Actinium Pharmaceuticals
ATNM
58 hedge funds and large institutions have $34.1M invested in Actinium Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 16 closing their positions.
91% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 11
75% more call options, than puts
Call options by funds: $957K | Put options by funds: $546K
1.53% less ownership
Funds ownership: 22.88% → 21.34% (-1.5%)
18% less funds holding
Funds holding: 71 → 58 (-13)
24% less capital invested
Capital invested by funds: $44.8M → $34.1M (-$10.7M)
75% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$1.16M |
| 2 |
BlackRock
New York
|
+$441K |
| 3 |
State Street
Boston,
Massachusetts
|
+$275K |
| 4 |
Goldman Sachs
New York
|
+$216K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$140K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$685K |
| 2 |
Two Sigma Advisers
New York
|
-$630K |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$430K |
| 4 |
Renaissance Technologies
New York
|
-$358K |
| 5 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$235K |
ATNM Hedge Fund Activity: Q3 2023 in Review
58 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q3 2023, worth a combined $34.1M — down 24% from $44.8M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ATNM and 4 opened new positions — a net loss of 12 holders — while 11 trimmed existing stakes and 21 added.
The largest buyer was Brandywine Global Investment Management, opening a new position worth an estimated $1.16M. The largest seller was Citadel Advisors, cutting an estimated $685K.
- 58 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q3 2023, down from 71 in Q2 2023.
- Funds reported $34.1M of Actinium Pharmaceuticals stock for Q3 2023, down 24% quarter-over-quarter.
- 4 funds opened new Actinium Pharmaceuticals positions in Q3 2023 and 16 closed out, a net change of -12 holders.
- The largest Actinium Pharmaceuticals buyer in Q3 2023 was Brandywine Global Investment Management, an estimated $1.16M added.
- The largest Actinium Pharmaceuticals seller in Q3 2023 was Citadel Advisors, an estimated $685K sold.
Based on aggregated 13F filings for Q3 2023.